Category Archives: Blog

The growing complexity of bioprocesses in the pharmaceutical industry, particularly in the development of innovative therapies such as oligonucleotides, is accelerating the adoption of digital technologies capable of improving understanding,

Solid-phase oligonucleotide synthesis (SPOS) is a highly efficient and reproducible process, but it has significant environmental limitations, primarily due to the high consumption of organic solvents and the generation of

Every 23 April, World Book Day invites us to reflect on the value of knowledge as a driving force for progress. In the field of biomedicine, the generation and transfer

This recognition from the European Medicines Agency (EMA) is one of the most demanding regulatory certifications. With this milestone, the company reinforces its commitment to operational excellence. Sylentis, empresa biofarmacéutica

Este reconocimiento de la Agencia Europea de Medicamentos (EMA) es una de las certificaciones reglamentarias más exigentes. Con este hito, la empresa refuerza su compromiso con la excelencia operativa. Sylentis,

On 15 December 2025, the CDTI hosted the IPCEI Health MED4CURE conference in Madrid, a key event for the Spanish biomedical ecosystem that brought together institutional leaders, companies participating in

Cardiovascular diseases (CVD) remain the leading cause of death worldwide. Despite advances in conventional medicine, many of these conditions are still treated with “one-size-fits-all” therapies that fail to reflect the

In October 2025, Sylentis participated in the annual conference of the Oligonucleotide Therapeutics Society (OTS) held in Budapest, one of the most important international meetings in the field of RNA-based

Interview with Ana Isabel Jiménez, Managing Director of Sylentis, on the occasion of OTS Budapest 2025 From 19 to 22 October 2025, Sylentis will participate in the Oligonucleotide Therapeutics Society